Understand how SHBG changes the interpretation of total and free testosterone, why test methods matter, and which questions to discuss with a clinician.
Total testosterone measures both protein-bound and unbound hormone, while free testosterone measures the unbound fraction, a distinction that matters when clinicians assess possible testosterone deficiency in the presence of altered SHBG.
This article is for informational purposes only and is not medical advice. Individual test interpretation and treatment decisions require assessment by a qualified clinician.
Total testosterone, often shortened to TT, describes testosterone circulating in the blood across its bound and unbound forms. It is an important part of the diagnostic framework in the European Association of Urology guideline on male hypogonadism. Hypogonadism is the clinical condition being assessed, rather than simply a label for an unfamiliar laboratory number.
The word “total” describes what the measurement includes. It does not mean that the result answers every question about testosterone status. A TT result combines hormone attached to proteins with hormone that is not attached to them, rather than reporting those fractions separately.
That distinction gives TT a specific clinical role: it provides a circulating hormone measurement that clinicians interpret alongside symptoms and relevant medical information. Understanding how the different testosterone measurements are defined helps separate the meaning of a test from the conclusions someone might draw from it.
Laboratory technique also deserves attention. The EAU guideline reports widespread use of immunoassays for TT and limited use of LC-MS/MS. It also describes inconsistent procedures before analysis, so the test name alone does not describe every detail of how a result was obtained.
The useful starting point is therefore not to rank total testosterone as a good or bad test. It is to understand what it measures and why a clinician might need another measurement to interpret it.
Free testosterone, often shortened to fT, is the fraction that is not bound to proteins. Unlike TT, it does not include the protein-bound portion. The EAU guideline describes fT evaluation as potentially helpful in assessing symptomatic male hypogonadism, particularly in older men with obesity.
However, “free testosterone” names the measurement of interest rather than one uniform laboratory procedure. The guideline distinguishes between measuring it with equilibrium dialysis, calculating it from other laboratory values and using direct immunoassays. Those approaches should not be treated as equivalent.
The EAU guideline identifies equilibrium dialysis as the most accurate method for measuring fT. This gives clinicians a reference point when discussing test methods. A report that says “free testosterone” without identifying the method leaves an important part of the interpretation unclear: how the laboratory produced that result.
The guideline also allows fT to be calculated using TT, SHBG and albumin. This is an estimate derived from those inputs rather than a separate direct measurement of the unbound fraction. Its interpretation therefore depends on the laboratory values used in the calculation.
A calculated result is best understood together with its inputs. The distinction between an estimate and a measurement matters when comparing reports or asking why a clinician selected a particular approach. Our explanation of the inputs behind calculated free testosterone provides further context for that discussion.
The EAU guideline cautions that available immunoassays do not accurately estimate fT and advises against using them for direct fT measurement. This warning concerns free-testosterone testing specifically. It should not be confused with the separate observation that immunoassays are widely used to measure TT.
The practical distinction is straightforward: the word “direct” does not establish accuracy. Asking which method produced the result is more useful than assuming that every laboratory report carrying the same test label offers the same information.
The EAU guideline notes that commercial immunoassay reference ranges may not clearly identify the population or the conditions used to establish them. That makes the reference interval part of the interpretation, rather than a universal boundary that can be carried unchanged from one report to another.
The guideline says limited evidence supports 220 pmol/L (6.4 ng/dL) as a potentially reliable fT threshold when SHBG is altered. It does not establish that value as a universal cutoff or make it interchangeable with every laboratory’s reference interval.
For a clinical discussion, the useful questions are which method was used and which reference interval applies to that method. A threshold without those details can appear more definitive than the underlying guidance supports.
SHBG stands for sex hormone-binding globulin, a protein involved in testosterone binding. The EAU guideline explains that SHBG affects the relationship between total and free testosterone. As a result, the same TT value may not represent the same fT level in every man.
This is why the comparison is not a contest between two competing tests. TT describes the combined circulating measurement. Free testosterone adds information about the unbound fraction, while SHBG helps clinicians understand how those measurements relate to each other.
The guideline lists hyperthyroidism and hepatic disease among conditions associated with higher SHBG. It also lists ageing, smoking and HIV/AIDS. Medication-related associations include anticonvulsants, oestrogens and thyroid hormone.
These details can give a clinician reasons to look more closely at the relationship between TT and fT. They also show why medication history and relevant health conditions belong in the discussion about a hormone panel.
Obesity, insulin resistance and type 2 diabetes are among the factors associated with lower SHBG in the guideline. Hypothyroidism and several medications also appear in that group. These are different clinical settings from those associated with higher SHBG, but they raise the same interpretive question about protein binding.
Such associations are clinical prompts, not proof that someone has abnormal SHBG or testosterone. A condition on either list does not establish an individual laboratory result. The guideline directs clinicians to evaluate relevant conditions and medications rather than infer hormone status from an association alone.
The EAU guideline strongly recommends measuring SHBG and calculating fT in conditions characterized by altered SHBG. It also recommends considering fT when a clinical condition may alter SHBG. The purpose is to clarify the interpretation of TT in that setting, not to replace one isolated number with another.
The guideline’s diagnostic framework brings the measurements back to the person being assessed. It calls for compatible symptoms and biochemical evidence, including low morning TT measured with a reliable assay. SHBG measurement and calculated fT are added when indicated rather than treated as mandatory tests for every man.
The EAU guideline recommends morning fasting TT testing. When TT is below 12 nmol/L, it recommends repeat testing so that low results are confirmed on at least two occasions. It also advises clinicians to work with local laboratories on appropriate thresholds.
This makes confirmation part of the assessment before treatment. A single TT or fT result does not establish hypogonadism by itself, and an SHBG result alone does not settle the diagnosis either. Symptoms and laboratory evidence need to be considered together.
Timing can also change the clinical context. The guideline says acute illness can cause functional hypogonadism and advises avoiding TT measurement during acute illness. That is a reason for clinicians to consider the circumstances of collection rather than interpret a report separately from the patient’s health at the time.
A discussion with a qualified clinician can focus on questions such as:
These questions support an informed consultation without turning the report into a self-directed treatment plan. For more background on confirmation, see why clinicians repeat an initially low testosterone result.
The treatment question follows the clinical assessment. The useful issue is not which test produces the more concerning number, but whether the combined evidence supports the clinician’s interpretation of symptoms and hormone status.
Total testosterone, free testosterone and SHBG are best viewed as connected measurements whose clinical meaning depends on symptoms, testing methods and the circumstances in which the blood was collected.
Confusing total testosterone with its unbound fraction can turn an SHBG-related interpretation question into an isolated-number judgment, a mistake Testostra addresses through evidence-led hormone education. Its explanations of testosterone testing and related biomarkers help readers understand how the measurements fit together while keeping educational context separate from personal diagnosis or treatment.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra